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Rational drug design implies usage of molecular modeling techniques such as
pharmacophore modeling, molecular dynamics, virtual screening, andmolecular docking
to explain the activity of biomolecules, define molecular determinants for interaction with
the drug target, and design more efficient drug candidates. Kinases play an essential role
in cell function and therefore are extensively studied targets in drug design and discovery.
Kinase inhibitors are clinically very important and widely used antineoplastic drugs. In
this review, computational methods used in rational drug design of kinase inhibitors are
discussed and compared, considering some representative case studies.
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KINASES AS TARGETS FOR DEVELOPING ANTICANCER DRUGS
Kinases belong to a large family of enzymes that catalyze transfer of high energy phosphate
group from adenosine triphosphate (ATP) to substrates, such as proteins (the protein-tyrosine
kinases, the serine-threonine specific kinases), lipids (phosphatidylinositol kinases, sphingosine
kinases), carbohydrates, and nucleic acids (Duong-Ly and Peterson, 2013). Phosphorylation of
the substrate modulates its activity and/or interaction with other molecules leading to different
physiological responses. It is estimated that 50% of all proteins are constantly undergoing reversible
phosphorylation and dephosphorylation, which emphasizes the role of protein kinases in almost
all aspects of cell function, including proliferation, cell growth, apoptosis, and signal transduction
(Graves and Krebs, 1999; Manning et al., 2002).
Dysregulated, overexpressed, or mutated protein kinases are found in many diseases, including
cancer, and over the past two decades they became extensively examined targets for the
development of new antineoplastic drugs (Blume-Jensen and Hunter, 2001; Cohen, 2002). There
are 53 kinase inhibitors (KIs) currently approved by the FDA (FDA, 2019), while over 200 potential
inhibitors are in different phases of clinical trials worldwide (Carles et al., 2018). Majority of the
approved drugs are orally active and effective against various malignancies (Table 1; Roskoski,
2019a,b).
Structures of the selected KIs commonly used for treatment of cancer are shown in Figure 1.
These drugs target different protein kinases that are frequently upregulated in cancer cells. The
epidermal growth factor receptor (EGFR) is a member of the ErbB family of tyrosine kinase
receptors that is overexpressed or mutated in non-small cell lung cancer and represents the primary
target for drugs such erlotinib and gefitinib (Bethune et al., 2010). Lapatinib and neratinib bind
to intracellular domain of the human epidermal growth factor receptor 2 (HER2/neu), another
member of the ErbB tyrosine kinases, which elevated levels are found in approximately 20–30%
of breast cancers (Collins et al., 2019). Imatinib possesses activity against non-receptor breakpoint
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cluster region (Bcr)-Abelson leukemia virus (Abl) tyrosine kinase
that is formed as a result of a chromosome rearrangement
and has been implicated in the pathogenesis of nearly all cases
of chronic myeloid leukemia (CML) and acute lymphoblastic
leukemia with the Philadelphia chromosome (Iqbal and Iqbal,
2014). Although imatinib is a relatively specific Bcr-Abl inhibitor,
it also inhibits the CD117 tyrosine kinase associated with
gastrointestinal stromal tumors and has consequently been
approved for this indication (Buchdunger et al., 2000). The
vascular endothelial growth factor family of receptors (VEGFR)
contains a tyrosine kinase domain which activation can lead to
induction of signaling pathways that regulate cell proliferation,
survival, and promotion of tumor angiogenesis (Morabito et al.,
2006). Agents that target VEGFR, including lenvatinib, sorafenib
and vandetanib, are frequently used for treatment of thyroid
cancers. Vemurafenib, dabrafenib, and encorafenib target BRAF,
a serine/threonine protein kinase which mutation is expressed
TABLE 1 | Therapeutic indications of selected FDA-approved protein kinase
inhibitors.
Therapeutic indication Drug
Breast cancer Everolimus, lapatinib, neratinib, palbociclib, ribociclib
Non-small cell lung cancer Afatinib, alectinib, brigatinib, ceritinib, crizotinib,
dabrafenib, dacomitinib, erlotinib, gefitinib, lorlatinib,
osimertinib
Leukemia Bosutinib, dasatinib, gilteritinib, ibrutinib, imatinib,
midostaurin, nilotinib, ponatinib
Melanoma Binimetinib, cobimetinib, dabrafenib, encorafenib,
trametinib, vemurafenib
Thyroid cancer Cabozantinib, lenvatinib, vandetanib
Renal cancer Axitinib, pazopanib, sorafenib, temsirolimus
Gastrointestinal cancer Regorafenib, sunitinib
FIGURE 1 | Structures of selected protein kinase inhibitors that have been approved for clinical use.
at about 50–60% of cutaneous melanomas where it leads
to continuous activation of mitogen-activated protein kinase
(MAPK) pathway and uncontrolled proliferation of cancer cells
(Yu et al., 2019).
Structure of Protein Kinases
The human genome encodes at least 518 protein kinases
(Manning et al., 2002). Out of them, 478 share highly conserved
catalytic domains. The remaining 40 do not share the sequence
similarity, but their folding is similar to the folding of “typical”
PKs (Caballero and Alzate-Morales, 2012). In 1991, Knighton
solved the X-ray structure of cyclic AMP-dependent PK and
described its structure for the first time. This description can
apply to all currently known protein kinases. The characteristic
architecture of the catalytic domain of PK consists of a small,
amino-terminal N-lobe and a large α-helical carboxy-terminal C-
lobe which are connected with a small hinge region (Figure 2;
Knighton et al., 1991). The N-terminal lobe is dominated by
five β-strands (β1–β5) and one conserved α-helix (helix C) that
occurs in active (αC-in) or inactive (αC-out) orientations. The
C-lobe consists of eight α-helices and four short conserved β-
strands (β6–β9) which include residues that participate in the
phosphorylation of protein substrates. The small and large lobes
form a catalytic cleft where ATP binds (Knighton et al., 1991;
Roskoski, 2019a). The hydrophobic residues of the cleft form a
binding pocket for ATP. The charged residues in the active site
bind and position the γ -phosphate of ATP and divalent cation
and take part in the catalysis (Knight et al., 2007).
Conserved residues play crucial roles in positioning
ATP, stabilizing the active-conformation and in the catalytic
mechanism, and they are mostly found in and around the active
site but also in other parts of the protein kinase domain (Knight
et al., 2007). Almost all protein kinases possess a conserved
K/E/D/D (Lys/Glu/Asp/Asp) signature that is important for the
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FIGURE 2 | The crystal structure of imatinib-bound form of the Abl kinase
(PDB accession code: 2HYY), colored as rainbow from N-lobe (blue) to C-lobe
(red). Imatinib is represented as ball and stick.
catalysis. Lysine and glutamic acid residues belong to the N-lobe,
and the two aspartic acid residues are found in the C-lobe. Lysine
residue binds to the α- and β-phosphates of ATP. Formation of
the salt bridge between the carboxylate group of aspartic acid
and the amino group of lysine stabilizes its interactions with the
α- and β-phosphates, and it is required for kinase activation
(Roskoski, 2015, 2019a,b).
The N-lobe contains a conserved flexible glycine-rich
GxGxxG motif (also called P-loop) between β1 and β2 that folds
over the nucleotide and places the γ -phosphate of ATP during
the catalysis (Taylor and Kornev, 2011). As mentioned above,
lysine from the β3-strand forms a salt bridge with the conserved
glutamate near the center of the protein-kinase αC-helix which
is necessary for the formation of the active enzyme, and this
structure corresponds to the “αC-in” conformation (Roskoski,
2015, 2019a,b).
The C-lobe is important for both the protein-substrate
binding as well as nucleotide binding (Roskoski, 2015). The C-
lobe contains a mobile activation loop of 20–30 residues which
can take open or closed conformation. The activation loop begins
with the DFG motif (Asp-Phe-Gly) and extends up to an APE
motif (Ala-Pro-Glu) (Modi and Dunbrack, 2019). In the active
conformation a divalent metal ion, Mg2+ (or sometimes Mn2+),
interacts with a highly conserved aspartic acid residue from the
DFG motif. It coordinates with the α and γ phosphates of ATP
and facilitates the phosphorylation and coordinates the ATP
binding (Adams, 2001). At the other end, glutamic acid fromAPE
motif is fixed by the formation of a salt bridge with arginine from
the C-lobe (Roskoski, 2015, 2019b). In addition to these, another
motif on the C-lobe is highly conserved suggesting it plays an
important role in the catalysis—HRD (rarely YRD) motif. The
aspartate residue of this motif is required for the orientation of
the hydroxyl group of the substrate peptide at the P-site and the
transfer of the phosphoryl group. Arginine residue interacts with
the phosphorylated activation segment thereby contributing to
its correct orientation. Histidine (or in rare cases tyrosine) is
considered to be involved in the maintenance of the conserved
rigid organization of the catalytic core (La Sala et al., 2016).
The main differences between tyrosine kinases and
serine/threonine kinases are found in the protein-substrate
binding site. In serine/threonine kinases, the phosphorylatable
serine or threonine of the protein substrate interacts with
backbone residues near the end of the activation segment. Basic
residues of the protein-substrate N-terminal interact with surface
acidic residues of the C-lobe. Additionally, peptide substrate is
fixed by serine in the glycine rich loop and lysine in the catalytic
loop and also to threonine in the P+1 loop. These three residues
are highly conserved in the majority of protein-serine/threonine
kinases, and they are positioning the target hydroxyl group of
a substrate in the catalytic cleft (near the γ -phosphate of ATP)
where the phosphotransfer reaction happens (P-site). Since
both serine and threonine hydroxyls are linked to the β-carbon,
they have similar mechanisms of the catalysis. On the other
hand, in tyrosine kinases, after DFG motif, there is a very stable
region that contains the three tyrosine phosphorylation sites.
The protein substrate chain positions in a manner that one
of the tyrosines is oriented with its hydroxyl group lying in
phosphorylation site P-site. The following tyrosine residue lies
in the P+1 site. Proline residue interacts with the tyrosyl residue
of the protein-substrate and is responsible for positioning the
P-site tyrosine in the phosphotransfer site. The tyrosine ring is
also positioned by Arg (Hubbard et al., 1994; Taylor et al., 1995;
Roskoski, 2015).
Moreover, many protein kinases are regulated by different
mechanisms such as dimerization, binding of allosteric effectors,
or other modifications important for subcellular localization
that can modulate their activity. Binding of an allosteric
modulator leads to conformational changes that mostly involve
structural reorganization of the activation loop, making it a
primary end point of allosteric regulation. Effectors or regulatory
subunits bind outside the catalytic site, causing the changes in
loop conformation through conformational changes of other
substructural elements. In most of the cases, regulators bind the
αC helix at different locations, allowing control of catalysis from
distal regions (Shi et al., 2006). Nevertheless, the αC helix is
not the only allosteric binding site, in fact, they are very diverse
(Figure 3; Ohren et al., 2004; Vanderpool et al., 2009; Jahnke
et al., 2010;Martin et al., 2012; Park et al., 2015; Rettenmaier et al.,
2015; Ung et al., 2018). Therefore, understanding the diversity of
allosteric regulatory sites among the kinase superfamily gives a
unique opportunity for the creation of novel selective allosteric
kinase antagonists (Lamba and Ghosh, 2012).
Active/Inactive States
Basically, protein kinases reside in one active state and
multiple inactive states (Figure 4). In active kinase conformation,
activation loop forms a cleft that binds the substrate. When the
substrate peptide binds, it interacts with the HRD motif (His-
Arg-Asp). Asp from the DFG motif binds a magnesium ion that
interacts directly with an oxygen atom of the β phosphate of
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FIGURE 3 | Diversity of allosteric binding pockets in different protein kinases. (A) ABL kinase in complex with fragment FRAG1 (PDB: 3MS9) (Jahnke et al., 2010); (B)
CDK2 in complex with 2 molecules of 8-anilino-1-naphthalene sulfonic acid (PBD: 4EZ7) (Martin et al., 2012); (C) CHK1 bound to allosteric inhibitor
(1S)-1-(1H-benzimidazol-2-yl)ethyl (3,4-dichlorophenyl)carbamate (PDB: 3JVR) (Vanderpool et al., 2009); (D) EGFR in complex with Mig6 protein (PDB: 4R3P) (Park
et al., 2015); (E) PDK1 with PIF pocket inhibitor RF4 (Rettenmaier et al., 2015); (F) MEK1 in complex with
5-bromo-N-(2,3-dihydroxyprpoxy)-3,4-difluoro-2-[(2fluoro-4-iodophenyl)amino]benzamide (PDB: 1S9J) (Ohren et al., 2004); (G) Sequence alignment of these kinases
showing which amino acids are involved in the binding of allosteric modulators.
ATP. This is followed by formation of a salt bridge between the
Glu from the C-helix with a Lys residue in the β3 strand. When
the salt bridge is formed, the lysine side chain forms hydrogen
bonds with oxygen atoms of α and β phosphates of ATP. The
Glycine-rich Loop of the N-lobe stabilizes the phosphates of the
bound ATP molecule during catalysis (Taylor and Kornev, 2011;
Modi and Dunbrack, 2019). In an inactive conformation, usually
the activation loop is blocking the substrate binding, and DFG
motif is incompatible with the binding ATP and magnesium ion
required for catalysis. Many attempts have been made in order
to achieve classification for these conformations and to study
interaction of inhibitors in different states (Mobitz, 2015; Ung
et al., 2018; Modi and Dunbrack, 2019), and they are all based
on the position of highly conserved DFG motif.
The most recent classification was published by Modi and
Dunbrack. They have divided kinase structures into three clusters
based on the spatial position of the DFG-Phe side chain into
DFG-in, DFG-out, andDFG-inter (intermediate) conformations.
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FIGURE 4 | Examples of inactive and active conformations of epidermal growth factor receptor (EGFR) kinase (PDB accession codes: 4HJO and 2GS6, respectively),
and their superimposition. The activation loop of inactive conformation (purple) is closed therefore blocking the substrate to enter catalytic loop, while activation loop in
active conformation (turquoise) is opened allowing the ATP to bind.
Each of these three clusters was further divided based on the
dihedral angles required to place the Phe side chain, resulting
in total of eight clusters: six for DFG-in and one cluster each
for the DFG-out and DFG-inter groups. DFG-in represents the
DFG motif orientations where DFG-Phe is packed against or
under the C-helix. It containsmany conformations, among all the
typical DFG-in active conformation belongs to this group. DFG-
out represents the structures where DFG-Phe is moved into the
ATP binding pocket. DFG-inter represents the conformations in
which the DFG-Phe side chain is out of the C-helix pocket but
has not moved completely to a DFG-out conformation. Usually
in this conformation DFG-Phe is pointing upward toward the β-
sheets while dividing the active site into two halves (Modi and
Dunbrack, 2019). This classification offers insight into active and
inactive kinase conformations which are of great importance in
structure-based design of kinase inhibitors.
Types of Kinase Inhibitors
Many reviewers have categorized KIs based on their binding
modes into three classes, labeled as types I, II, and III
kinase inhibitors (Roskoski, 2016; Bhullar et al., 2018). Type
I inhibitors, such as gefitinib, bind to the active DFG-in
conformation of a kinase in the phosphorylated ATP catalytic
site, and they usually contain a heterocycle that mimic the
purine ring of ATP. Considering that the ATP active site is
highly conserved among different protein kinases, these ATP-
competitive inhibitors display low selectivity profile which may
lead to off-target side effects. While the physiological relevance
of many off-target effects is still unclear, it was demonstrated
that the lack of selectivity is connected with preclinical and
clinical cardiotoxicity of kinase inhibitors (Force and Kolaja,
2011; Yang and Papoian, 2012). Possible mechanism behind
the KI induced cardiotoxicity lies in binding of these drugs to
colony-stimulating factor 1 receptor (CSF1R) (Hasinoff, 2010).
Type II inhibitors, such as imatinib, bind to the inactive (DFG-
out) conformation of a kinase in the unphosphorylated ATP
catalytic site (Dar and Shokat, 2011). Zuccotto introduced
type I½ inhibitors as compounds that bind to active ATP
catalytic site as type I inhibitors but elongate into the back
cavity of the ATP site giving rise to interactions specific
for type II pharmacophore. These inhibitors represented by
dasatinib, lapatinib, and vemurafenib, display higher selectivity
profile as compared to Type I KIs (Zuccotto et al., 2010).
Types III and IV are allosteric inhibitors that bind outside
the ATP-binding site. Type III includes trametinib that binds
to the allosteric site close to the ATP pocket, whereas Type
IV inhibitors bind to a pocket distant from the ATP-binding
site. Bivalent inhibitor spanning two regions of the protein
kinase is termed as Type V (Wong et al., 2017), while KIs
that form an irreversible covalent bond with the catalytic
site represent Type VI inhibitors (afatinib and ibrutinib)
(Roskoski, 2016).
Developing and Overcoming Resistance to
Kinase Inhibitors
Despite the significant advances achieved by the use of
protein kinase inhibitors, drug resistance remains one of the
greatest challenges toward successful cancer treatment. Various
mechanisms can underpin the development of resistance to
KIs, including alterations in protein kinases, aberration of
downstream pathways, or bypass mechanism that activates
parallel signaling pathways (Holohan et al., 2013). Mutations
of Bcr-Abl kinase domain were found in over 90% of patients
with CML who relapsed after an initial response to imatinib.
These mutations include different amino acid substitutions at
the active site residues or changes in the kinase flexibility that
impair its ability to adopt the inactive conformation required
for optimal imatinib binding (Shah et al., 2002). Dasatinib
is a novel Abl kinase inhibitor that can bind to both the
active (mutated) and inactive (normal) conformations of Bcr-
Abl, and its activity has been demonstrated in all imatinib-
resistant CML patients, with the exception of those with the
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T315I mutation that prevents formation of critical hydrogen
bond (Shah et al., 2004; Burgess et al., 2005). Docking of
dasatinib to three Bcr-Abl conformations (active, inactive, and
intermediate inactive) showed that dasatinib binds preferentially
to an active conformation, and that binding affinity significantly
decreases when the kinase adopts inactive conformation (Laurini
et al., 2013). Drug combinations targeting different upstream and
downstream components within a single pathway, or targeting
parallel kinase pathways, have been proved in clinical trials as
an efficient method to overcame or delay therapeutic resistance.
For instance, treatment with dabrafenib, a selective BRAF
inhibitor, and trametinib, a selective MAPK kinase inhibitor,
significantly improved progression-free survival of melanoma
patients (Flaherty et al., 2012).
IN SILICO METHODS USED IN DRUG
DESIGN
Since the approval of imatinib in 2001, protein kinases have
received significant attention from academic and pharmaceutical
companies, reflected in a large number of publications, solved
crystal structures, and identified small molecule inhibitors for
about one-fifth of the human kinome (Wu et al., 2015b).
Considerable progress in this field is much owed to the use
of computational methods that were able to provide valuable
information on structural characteristic of both the kinase and
the ligand that are important for favorable interaction and
desired inhibitory activity (Agafonov et al., 2015). To design
inhibitors for protein kinases it is necessary to understand the
structure and dynamics of these enzymes, substrate recognition,
and reaction of phosphorylation, product release as well as
differences between active and inactive conformations.
There are two main approaches within the framework of
computer-aided drug design (CADD): structure-based drug
design (SBDD), and ligand-based drug design (LBDD). SBDD
is based on structural information gathered from biological
targets and includes in silico methods such as molecular
docking, structure-based virtual screening (SBVS), andmolecular
dynamics (MD). In contrast, in the absence of information
on targets, LBDD relies on the knowledge of ligands that
interact with a specific target, and these methods include
ligand-based virtual screening (LBVS), similarity searching,
quantitative structure-activity relationship (QSAR) modeling,
and pharmacophore generation (Ferreira et al., 2015). Over the
last years, a large number of studies have reported successful
use of CADD in design and discovery of new drugs (Lu
et al., 2018b). In this study we provide the comprehensive
review of computational tools that led to discovery, design and
optimization of KIs as anticancer drugs.
Ligand-Based Methods in Drug Design
QSAR modeling involves the formation of a mathematical
relationship between experimentally determined biological
activity and quantitatively defined chemical characteristics that
describe the analyzed molecule (descriptors) within a set of
structurally similar compounds. The QSAR concept originated
in the 1860s, when Crum-Brown and Fraser proposed the idea
that the physiological action of a compound in a particular
biological system is a function of its chemical constituent, while
the modern era of QSAR modeling is associated with the work
of Hansch et al. in the early 1960s (Hansch et al., 1962). The
aim of the QSAR modeling is to utilize the information on
structure and activity obtained from a relatively small series of
data to ensure that the best lead compounds enter further studies,
minimizing the time and the expense of drug development
process (Cherkasov et al., 2014).
Classical 2D-QSAR models correlate physicochemical
parameters, such as electronic, hydrophobic or steric
characteristics of compounds, to biological activity, while
the more advanced 3D-QSAR modeling adds quantum chemical
parameters. One of the first approaches used in deriving
3D-QSAR models was CoMFA (comparative molecular field
analysis). With this analysis, molecules were described with
electrostatic and steric fields, which were correlated to biological
activity by means of partial least squares regression (PLS)
(Cramer et al., 1988). In addition to the steric and electrostatic
descriptors, another approach used in deriving 3D-QSAR
models was Comparative Molecular Similarity Index Analysis
(CoMSIA). CoMSIA approach additionally uses three novel
fields comparing to CoMFA, describing the ligand’s hydrophobic
properties, the presence of the hydrogen bond donors (HBD),
and the presence of hydrogen bond acceptors (HBA) (Klebe
et al., 1994). The main limitation of the CoMFA/CoMSIA
methods is that they are largely dependent on the alignment of
3D-molecular structures which is often a slow process prone
to subjectivity. Recently, modern QSAR programs that use
new generation of 3D-descriptors, so-called grid-independent
(GRIND) descriptors, have been developed and used for
multivariate analyses and 3D-QSAR modeling (Pastor et al.,
2000; Duran et al., 2009; Smajic´ et al., 2015; Gagic et al., 2016b).
Recent cases of reported QSAR studies aimed at providing
useful information to guide the discovery of new potent KIs are
listed in Table 2. Some of them will be discussed in this chapter.
Koneru et al. have used QSAR combined with molecular
dynamics to redesign second-generation Src kinase inhibitor
RL-45 in order to withstand the gatekeeper residue mutation





Mer 3D Pentacle Shiri et al., 2016
Lyn 2D JMP Naboulsi et al., 2018
HER2, EGFR 3D SYBYL de Angelo et al., 2018
EGFR 2D and 3D SYBYL Simeon et al., 2019
IKK-β 2D and 3D Discovery studio;
Schrödinger suite
Wang et al., 2019a
EGFR 3D SYBYL Zhao et al., 2019a
Src 3D Vlife MDS Koneru et al., 2019
VEGFR-2 3D MOE Mohamed et al., 2019
PKMYT1 2D MOE Najjar et al., 2019
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and enhance binding affinity. They integrated fragment-based
drug discovery (FBDD) technique with QSAR and molecular
dynamics to assess novel Src kinase inhibitors. Newly designed
compounds were assumed to be able to mitigate mutation-
related Src kinase resistance and to bind more efficiently to
the kinase active site and were proposed for further synthesis
(Koneru et al., 2019). Wang et al. applied QSAR studies on a
series of 2-acylamino-3-aminothienopyridine analogs in order
to design new IKK-β inhibitors (Wang et al., 2019a). Obtained
information on physicochemical, structural, electrostatic, and
steric properties revealed that bulky aryl substituents at position
C3 on the piperidine ring have favorable effect on activity, which
led to the design of an in-house library. Compounds with best
predicted activities were further subjected to docking studies.
Based on these results two new compounds B01 and B02 were
identified as potential IKK-β inhibitors, with predicted pIC50
activities of 7.18 and 7.17, and binding affinities of 41.6 and 40.1
kcal/mol, respectively.
Comparative 2D- and 3D-QSAR studies, followed by
molecular docking were conducted on a series of quinazoline
derivatives acting as EGFR inhibitors (Noolvi and Patel,
2013). According to the 2D-QSAR multiple linear regression
(MLR) model, anticancer activity of quinazoline derivatives
was influenced by lipophilicity and number of hydrogen bond
donors. Presence of short chain ethers such as methoxy-, ethoxy-
at C-6 and C-7 positions of quinazoline was found favorable for
the activity, while N-containing groups should not be directly
attached to the quinazoline ring. 3D-QSAR kNN-MFA (k-nearest
neighbor molecular field analysis) revealed that the presence of
electronegative groups on the anilino moiety site, electropositive
groups at position C7, and a bulky aromatic substituent at C4
increases the EGFR kinase inhibitory activity.
Virtual screening (VS) refers to a group of in silico methods
widely used in drug discovery to search large-scale compound
databases in order to select a more manageable number of
candidates with the highest probability of displaying the desired
biological activity (Gagic et al., 2016a; Oluic et al., 2017; Vucicevic
et al., 2017; Banegas-Luna et al., 2018). This method has been
very popular among pharmaceutical companies since it enables
developing drugs in time and cost-effective manner and increases
the chance of selected candidates to reach clinical studies.
Considering the constant improvement of computational power,
it is expected that in the near future VS will be a reasonable
alternative to high throughput screening (HTS) (Kumar et al.,
2015). There are generally two approaches to screen molecular
libraries: LBVS that will be discussed in this section and SBVS.
LBVS is often applied when there are known active
compounds, but the target of action is not known, or the
crystallographic structure of the protein is not available. These
active compounds are then used as ligands to screen molecular
libraries based on the similar property principle, which states
that structurally similar compounds should possess similar
biochemical properties (Nikolic et al., 2015; Bajorath, 2017).
For each compound from the virtual library, the similarity with
the known active is calculated. Many different strategies for
measuring similarity have been developed, including Cosine
coefficient, Euclidean distance, Soergel distance, and Tanimoto
coefficient (Bajusz et al., 2015). Compounds are ranked based on
the similarity score and those at the top are selected as virtual
hit molecules for further optimization and synthesis. Modern VS
protocols include additional filtering steps in order to exclude
compounds that e.g., have low similarity score, do not fall within
the Lipinski’s rule of five, are not feasible for synthesis or are not
available for purchase (Neves et al., 2018).
Besides similarity searches, pharmacophore search is one
of the most commonly used LBVS techniques. Given a list
of known actives, pharmacophore model can be derived to
define the minimum structural requirements that molecule
must possess in order to exhibit good activity profile (Vittorio
et al., 2019). It is then possible to search large databases,
such as PubChem (Kim et al., 2019), ChEMBL (Mendez et al.,
2019), and DrugBank (Wishart et al., 2018), for identification
of lead compounds that fit to the pharmacophore structure
(Bacilieri and Moro, 2006). Several studies that describe the
use of LBVS methodology in discovery of potential kinase
inhibitors have been listed in Table 3. Pharmacophore-based
VS model was employed to search for new tumor progression
locus-2 (Tpl2) inhibitors (Teli and Rajanikant, 2012). Tpl2 is
a serine/threonine kinase in the MAPK signaling pathway that
regulates cell proliferation, survival, and death and participates
in many processes of tumor development (Lee et al., 2015).
For this purpose, Asinex database was screened using PHASE
3.0 module of the Schrodinger molecular modeling software
which resulted in six potential Tpl2 kinase inhibitors. A
3D QSAR pharmacophore model was developed from the
structures of known inhibitors of MAPK1 (ERK2) and used
for virtual screening of ZINC database (Irwin et al., 2012) that
contains over 750 million compounds, DrugBank with 13,443
drugs (Wishart et al., 2018), NCI (https://cactus.nci.nih.gov/
ncidb2.2/) with 250,250 structures, Maybridge (https://www.
maybridge.com) with over 53,000 compounds and Chembank
database (Seiler et al., 2008). Top screened compounds were
then subjected to molecular docking that identified new
scaffolds with high potency and selectivity against ERK2
(Larif et al., 2014).
It can be concluded that VS strategies, especially
Pharmacophore-based VS and combined use of VS and
molecular docking, can be a reliable tool for future discovery of
new KIs and have a potential to replace a HTS that is costly and
time consuming process.
TABLE 3 | Selected studies that have used LBVS in the design of kinase inhibitors.
Target kinase Software package References
EGFR PHASE Sudha et al., 2015
CDK2 SYBYL Zhang and Ren, 2018
ERK-1/2 QSAR-Co Halder et al., 2019
VEGFR 2 Discovery studio Sobhy et al., 2019
ALK PHASE James et al., 2019
CDK9/Cyclin T1 LigandScout Hussain and Verma, 2019
FGFR1 Discovery studio Liu et al., 2020
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Case Studies
Application of quantitative structure-activity relationship in
structure elucidation of Lyn kinase inhibitors
The generalized linear model (GLM) and the artificial neural
network (ANN) QSAR models were combined with structural
analysis in order to define pharmacophore of Lyn kinase
inhibitors (Naboulsi et al., 2018). Lyn kinase is a member of the
Src family of tyrosine kinases that was found to be correlated
with chemotherapeutic resistance of cancer cells in patients
with CML (Chakraborty et al., 2013; Aira et al., 2018). Derived
pharmacophore for the inhibition of Lyn kinase suggested the
presence of planar heterocyclic ring that contains HBD and
HBA, a spacer that allows free bond rotation and central
hydrophobic area that is linked to the aromatic ring substituted
with lipophilic groups. These structural futures can be found in
nilotinib and dasatinib that are approved for treatment of CML
(Figure 1). Pyrimidine moiety of nilotinib has the role of the
hydrogen bonding region; the attached amino group serves as
a spacer that is linked to hydrophobic benzyl group connected
with another aromatic ring that is substituted with lipophilic
trifluoromethyl group and methylimidazole. Aminopyrimidine
moiety is also present in dasatinib that is indicated in CML
patients that developed resistance to nilotinib (Okabe et al.,
2011). Dasatinib, instead of central hydrophobic benzene ring,
contains thiazole connected to an aromatic ring with lipophilic
substituents. Results of these QSAR studies can be of great help
in future design and lead to optimization of new, more potent
Lyn kinase inhibitors for treatment of patients with imatinib and
nilotinib-resistant CML.
Quantum mechanical based quantitative structure-activity
relationship of N-phenylquinazolin-4-amine derivatives as
epidermal growth factor receptor inhibitors
Recently, Simeon at al. applied several 2D- and 3D-QSAR
methodologies on a series of EGFR inhibitors, derivatives of
N-phenylquinazolin-4-amine (Simeon et al., 2019). 2D QSAR
models were created using physico-chemical descriptors, e-state
indices and molecular fingerprints, while 3D-QSAR models were
developed using CoMFA, CoMSIA, and quantum mechanical
(QM)methods. Based on the calculated statistical parameters, the
QM-QSAR model displayed better predictive power compared
to the other models. Development of this model started with
docking of N-phenylquinazolin-4-amine analogs to the EGFR
active site and calculation of pairwise interaction energies
between each inhibitor and amino acid residues using quantum
mechanics. Distances that hold information about the position of
the quinazoline ring and the aniline pharmacophores within the
active site of the EGFR were extracted and used as descriptors
for the QM-QSAR model. Combined 2D- physico-chemical and
QM-QSAR model showed even better predictivity and provided
more precise information about structural characteristics that
are important for EGFR inhibitory activity. Based on the
results of this study, it can be concluded that a combination
of classical and more advanced quantum mechanical QSAR
methodologies represents a good concept for future design of new
EGFR inhibitors.
Discovery of potential FGFR1 inhibitors using
pharmacophore-based virtual screening
Pharmacophore-based VS protocol was developed in Maestro
9.0 software package (https://www.schrodinger.com/) and used
to screen SPECS database (http://www.specs.net) for potential
FGFR1 inhibitors (Zhou et al., 2015). Database was previously
filtered to extract only compounds with drug-like properties that
comply with the Lipinski’s rule of 5. Activities of top ranked
compounds were predicted with constructed atom-based 3D-
QSAR model, and those with highest activities were purchased
for experimental enzyme assay. Nineteen hits exhibited moderate
inhibitory activity with more than 50% FGFR1 inhibition at
50µM concentration and IC50 values of most active compounds
were 7.9 and 55.5µM. It should be mentioned that the identified
compounds had low structural similarity with previously
reported FGFR1 inhibitors and offered novel chemical scaffolds
for future optimization of FGFR1 inhibitors.
Structure based methods in drug design
Recent progresses in the field of X-ray crystallography, Nuclear
Magnetic Resonance (NMR) techniques, and cryo-electron
microscopy (CEM) caused a significant increase in the number of
known 3D structures of proteins (Sun et al., 2011). With known
3D structures of proteins, docking became a method of choice in
drug design.
Molecular docking predicts the most probable orientation of
one molecule toward another (Lengauer and Rarey, 1996). It can
be performed between a small molecule and a target protein
(ligand-protein docking) or between two proteins (protein-
protein docking). In ligand-protein docking, which will be
discussed here, the samples of conformations of small molecules–
ligands are placed into the binding sites of protein, where scoring
functions are used to calculate which of these conformations best
fits the target protein binding site (Sousa et al., 2006; Warren
et al., 2006). Overall, docking protocols include search algorithm
and a scoring function. Initially, the search algorithm is used to
orient small molecules in the target binding site (Taylor et al.,
2002). Sampling of conformational space has to be carried out
with acceptable accuracy to determine the conformation that
best fits the binding site, but fast enough to evaluate a large
number of docked ligands. With today’s computer power it
would be impossible to explore all the degrees of freedom for
ligand and protein complex. Therefore, there are different ways
to overcome this problem. Search algorithms can be systematic
and stochastic and deterministic (Novicˇ et al., 2016). Systematic
search algorithms sample the search space at predefined intervals
while stochastic make random changes until a user-defined
termination criterion is met, and because of that outcome
can vary (Morris and Lim-Wilby, 2008). Search algorithm is
then followed by scoring function that estimates the affinity of
ligand through the assessment of interactions between ligands
and potential targets (Kitchen et al., 2004). Scoring functions
can be physics-based, empirical, knowledge-based, and machine
learning-based (Liu and Wang, 2015; Li et al., 2019). The physic-
based scoring function computes the free energy of binding by
summing up the van der Waals and electrostatic interactions
between the protein–ligand (enthalpy), and adding the torsion
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entropy of ligand as well as the solvation/desolvation effect
described by explicit and implicit solvent models (Huang et al.,
2006; Liu andWang, 2015). Empirical scoring function estimates
the binding affinity of a complex by accumulating significant
energetic factors for protein–ligand binding (hydrogen bonds,
hydrophobic effects, steric clashes, etc.). It uses a training set
with known binding affinities of protein–ligand complex and
optimizes the weights of the energetic factors by the means of
regression analysis (Eldridge et al., 1997; Liu and Wang, 2015).
The knowledge-based scoring functions also uses structural
information of large set of known protein–ligand complexes and
converts it into distance-dependent Helmholtz free interaction
energies (Muegge and Martin, 1999; Li et al., 2019). Machine-
learning based scoring functions for docking are getting more
interests nowadays. These methods combine QSAR analysis
and protein–ligand interaction evaluation. They combine QSAR
analysis and protein–ligand interaction evaluation. The training
set of protein–ligand complexes with known structures and
binding affinities is required for a model calculation. Structural
interaction fingerprints between a protein and a ligand are coded
with certain descriptors (electrostatic interactions, hydrogen
bonds, or aromatic stacking, surface or shape properties,
molecular weight, number of rotatable single bonds, etc.). Then,
different machine-learning algorithms are employed for variable
selection (Deng et al., 2004; Zhang et al., 2006).
Molecular docking can be employed in many parts of
drug discovery process, such as structure–activity studies, lead
optimization, structure based virtual screening, binding modes
defining, chemical mechanism studies, etc. (Nikolic et al., 2013;
Bautista-Aguilera et al., 2014; Oluic et al., 2017; Albert et al.,
2019). Most popular docking programs are DOCK (Kuntz
et al., 1982), Autodock (Morris et al., 2009), AD Vina (Trott
and Olson, 2010), GOLD (Verdonk et al., 2003), GLIDE from
Schrödinger suite (Halgren et al., 2004), and they mostly differ
in search algorithms and scoring functions they use. It is always
recommendable to explore several different docking programs
and then decide on the best one for the specific protein-
ligand complexes.
For the last decade, molecular docking has been widely
used in design of protein kinase inhibitors (Table 4). Tsou
et al. designed 4-(phenylaminomethylene) isoquinoline-1, 3(2H,
4H)-dione derivatives, an original class of potent inhibitors
that selectively inhibit CDK4 over CDK2 and CDK1 activities.
They used SAR and docking to identify interactions between
the ligands and residues of the protein’s ATP binding pocket
and to find interactions with amino acids unique to CDK4
(His82, Val83, and Asp84) and to optimize compounds with
improved activity and selectivity toward CDK4 (Tsou et al.,
2008). Gopalsamy et al. identified a compound as B-Raf
inhibitor from high throughput screening (HTS) and used
docking into the crystal structure of B-Raf-Sorafenib complex
(1UWH) (Wan et al., 2004) to identify important protein–ligand
interactions (two hydrogen bonds with Glu500 and Asp593,
and hydrophobic interactions with Ile462, Trp530, Phe582, Ile
512, His 573, and Ile 571) and to optimize the scaffold to
obtain compound with improved potency (Gopalsamy et al.,
2009). In 2018, Amr et al. synthetized a series of macrocyclic
TABLE 4 | Selected studies that have used docking in the design of kinase
inhibitors.
Target kinase Software package References
EGFR Maestro Hu et al., 2017
VEGFR-2, CDK-2 and PDGFRβ MOE Amr et al., 2018
Bcr-Abl Autodock Kale and Sonwane, 2018
PKMYT1 GOLD Platzer et al., 2018
EGFR, PDGFR-β GOLD Fischer et al., 2018
Pim-1 MOE Mohareb et al., 2019
PAK4 Glide Gao et al., 2019
Bcr-Abl Discovery studio Melge et al., 2019
EGFR Glide Debnath et al., 2019
PI3K AutoDock Wang et al., 2019b
Pim-1 AutoDock Hazhazi et al., 2019
VEGFR-2 GOLD Zhao et al., 2019b
PKC Glide Wang et al., 2019c
EGFR MOE Khodair et al., 2019
pyrido-pentapeptide candidates, and identified their activity
in vitro on several kinases. Following docking study of the best
compound into VEGFR-2, EGFR, PDGFR, provided information
of the binding mode and important protein-ligand interactions
which can be further used as a guideline for future design
(Amr et al., 2018). In their efforts to design 2-phenazinamine
derivatives as Bcr-Abl tyrosine kinase inhibitors, Kale and
Sonwane combined molecular docking studies with G-QSAR
(Group-Based QSAR). Their in silico studies predicted better
activity for the thiazolidones and benzenesulfonyl derivatives of
phenazinamines than doxorubicin. However, in vitro cytotoxic
activity was good, though still less than of doxorubicin (Kale and
Sonwane, 2018).
Molecular dynamics (MD) is a simulation technique for
studying time dependent evolution of molecular system. Relying
on principles of classical mechanics, in MD simulations,
positions, and velocities of atoms are computed by classical
(Newtonian) laws of motion (Klepeis et al., 2009). The forces
acting on these atoms are computed using potential energy
functions known as force fields. All common force fields
express potential energy through bonded terms (covalent bond-
stretching, angle-bending, torsion potential, improper torsions)
and non-bonded terms (Lenard Jones repulsion and dispersion
and Coulomb electrostatics) (Vanommeslaeghe et al., 2014).
Several force fields were found to provide quite accurate
representations of the structure and dynamics of a number
of small globular proteins on the sub-microsecond timescale
(Beauchamp et al., 2012). Most commonly used force fields today
are CHARMM (Yin and MacKerell, 1998), AMBER (Weiner
et al., 1984; Cornell et al., 1995), GROMOS (Oostenbrink et al.,
2004), OPLS (Jorgensen et al., 1996), and COMPASS (Sun, 1998)
force fields since they include various chemical groups present in
macromolecules and drug-like entities.
Recent algorithmic advances and increase in computational
power have enabled simulation studies of protein systems
on biophysically-relevant timescales. Combined with modern
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improvements in the quality of force field parameters, protein
structure prediction and modeling has advanced impressively
(Beauchamp et al., 2012; Raval et al., 2012; Piana et al., 2014).
Providing structural and dynamical insight into the studied
molecular system difficult to obtain experimentally, as well
as thermodynamics and kinetic understanding of the system,
MD simulations are usually referred to as “computational
microscopes” (Dror et al., 2012). In this review, we discuss the
usefulness of MD and MD-based methods in the discovery of
kinase inhibitors through different case studies presented below.
Structure-based virtual screening (SBVS) is based on the
knowledge of the 3D structure of the target protein, obtained
by X-ray crystallography, NMR, cryo-EM or homology modeling
(Lionta et al., 2014). Nowadays, the SBVS methods are enabled
thanks to a large number of 3D structural information deposited
in the PDB. As described above, by using the 3D structural
information of the protein target, we are now able to investigate
the basic molecular interactions involved in ligand-protein
binding and understand experimental results up to atomic levels.
In SBVS, large libraries of commercially available drug-like
compounds that are computationally screened against proteins of
known structure and those that are predicted to bind well can be
experimentally tested (Benod et al., 2013; Vucicevic et al., 2016;
Oluic et al., 2017).
Case Studies
Structure-based design of imidazo
[4,5-b]pyridin-2-one-based p38 mitogen-activated protein
kinase inhibitors
Using structure-based drug design, Kaieda et al. have identified a
series of potent p38 mitogen-activated protein kinase inhibitors.
First they identified the lead compound with moderate inhibitory
activity toward p38 MAP kinase by means of high-throughput
screening. The lead compound was then crystalized with the
MAP kinase. The X-ray crystallographic results showed that
carbonyl group of the compound forms two hydrogen bonds
with the backbone amide of Met109 and Gly110 of the enzyme
(Figure 5A). The hinge backbone conformation of their crystal
structure was different from that typically seen in protein kinases.
Namely, usually the backbone amide and carbonyl group of
Met109 are directed toward the ATP binding site and accessible
for creation of hydrogen bonding with ligand. In the obtained
crystal structure a flip of the peptide bond between Met109 and
Gly110 was noticed which led to a switching of the hydrogen-
bond acceptor and donor distribution around the peptide plane,
instead. It was assumed that this flip could be responsible for
the high kinase selectivity. After switching the scaffold of the
carbonylpiperidine group while maintaining this binding mode,
a series of synthetized imidazo[4,5-b]pyridin-2-one derivatives
were identified as potent inhibitors of the p38 MAP kinase
(Figure 5B; Kaieda et al., 2019).
Discovery of novel Pim-1 kinase inhibitors by support vector
machine, pharmacophore modeling and molecular docking
In 2011 Ren et al. reported the discovery of novel potent
Pim-1 inhibitors by combining ligand- and structure-based
filtering methods. In order to find new molecules, a pipeline
was created that consisted of support vector machine-based
VS (SVM-based VS), pharmacophore-based VS (PB-VS), and
docking-based VS (DB-VS) and screened approximately 20
million molecules. Protocol was evaluated by using the
library which contained 203 known Pim-1 inhibitors and
around 117,000 generated decoys. For validation of the
performance of VS, the percentage of predicted compounds in
known inhibitors, percentage of known inhibitors in predicted
compounds, as well as enrichment factor were calculated. The
combined protocol showed much better performance than
solely SB-VS, PB-VS, and DB-VS. Finally, 47 compounds
were selected for further in vitro Pim-1 kinase inhibitory
assay for an inhibitor concentration of 10µM, and 15
compounds showed nanomolar level or low micromolar
inhibition potency against Pim-1. In conclusion, new scaffolds
with the potential for the future chemical development were
found (Ren et al., 2011).
FIGURE 5 | Crystal structures of p38 mitrogen-activated protein (MAP) kinase with imidazo[4,5-b]pyridin-2-one derivatives. (A) Lead compound found by HTS (PDB:
6M95). (B) Potent p38 MAP kinase inhibitor designed using structure-based drug design (SBDD) approach (PDB: 6M9L).
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Discovery of pazopanib, vascular endothelial growth factor
family of receptor inhibitor
In 2008 Harris et al. published a paper explaining their discovery
of pazopanib. That was a good example of usage of homology
modeling and SBDD in the discovery of a drug that is today
on the market. Since the crystal structure of VEGFR2 was not
available at that time, a homology model of the VEGFR2 enzyme
based on FGFR crystal structures was created to predict the
binding mode of dimethoxyquinazoline analogs. It was noticed
that the pyrimidine and the quinazoline bound similarly in the
ATP binding site, making the hydrogen bonds with the Cys919
of the backbone (Figure 6). Crystallization of these compounds
with VEGFR2 confirmed in silico results (PDB: 1Y6A, 1Y6B).
Finally a series of new analogs was designed, synthetized, and
tested in vitro, which led to the discovery of pazopanib (Harris
et al., 2005, 2008).
Rational discovery of dual-indication multitarget
phosphodiesterase/ kinase inhibitor
One of the latest studies published this year by Lim et al.
combined molecular docking with other bioinformatics tools,
with the goal of finding multi-target-multi-indication drugs (Lim
et al., 2019). They have used structural and chemical genomics
data and combined tools from bioinformatics, chemoinformatics,
protein-ligand docking, and machine learning to create a
novel structural systems pharmacology platform−3D-REMAP.
It used four networks as input: 1. protein–ligand association,
2. off-target, 3. ligand–ligand similarity, and 4. protein–protein
similarity. The protein–ligand associations were obtained from
ChEMBL, DrugBank, and from other publications about kinome
assays (Christmann-Franck et al., 2016; Drewry et al., 2017;
Klaeger et al., 2017; Merget et al., 2017) and protein structure-
based off-target prediction from binding pocket similarity
search and protein–ligand docking. Ligand–ligand similarity was
calculated in MadFast software from ChemAxon, and protein–
protein similarity was run through BLAST. Moreover, to validate
and show advantages of their platform, they searched for
marketed drugs that could be dual-indication agents. In their
study, they focused on drugs that could reduce the cardiotoxicity
of anti-cancer therapy. They predicted that levosimendan, a
phosphodiesterase (PDE) inhibitor which is used for heart
failure, also inhibits serine/threonine-protein kinase RIO kinase
1 (RIOK1) and several other kinases [Ca2+/calmodulin-
dependent protein kinase II (CAMK2), FMS-like tyrosine kinase
3 (FLT3), RIOK3, etc.]. To validate their results they tested anti-
cancer activity of levosimendan for more than 200 cancer cell
lines. Their experimental results showed that levosimendan is
active against several cancers, particularly lymphoma, through
the inhibition of RIOK1 and its RNA processing pathway (Lim
et al., 2019). Since this study is brand new, the time will tell
whether levosimendan will be a candidate for clinical research.
Fragment-based drug design of kinase inhibitors
Discovery of kinase inhibitors is a highly competitive process
wherein teams of experienced researchers, both from academia
and industry, use all the previous knowledge and new ideas
to provide more effective therapies for patients. Depending on
the available methodologies, one research group may start their
drug discovery project with a high-throughput screening (HTS)
campaign and search for the bioactive (HIT) compounds against
the studied kinase. Selected HIT molecules usually possess drug-
like properties and should be further optimized with the aid of
lead optimization techniques. Contrary to drug-like molecules,
fragments have a smaller number of heavy atoms (HA) and they
should comply with Rule of Three (RO3), in which molecular
weight is <300 Da, number of hydrogen bond donors and
acceptors should be ≤3 and clogP is ≤3 (Congreve et al., 2003).
Fragment molecules tend to show high micromolar to
millimolar affinities for a certain biological target. The advantages
of using fragments in drug design studies of novel kinase
inhibitors are numerous:
- Fragments displaying affinity to the examined biological
target can overcome the entropy barrier and their
binding is related to the favorable enthalpy contribution
(Murray and Verdonk, 2002);
FIGURE 6 | Crystal structures of initial screening hits for inhibitors of the vascular endothelial growth factor (VEGF) that lead to the discovery of pazopanib. (A) PDB:
1Y6A, (B) PDB: 1Y6B.
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- Comparing to drug-sized molecules, pharmacokinetic and
physicochemical properties of fragments could be more
efficiently optimized (Leach and Hann, 2011);
- Drug-sized molecules may suffer from a potential loss
of complementarity with the studied targets, whereas the
fragments seldom possess functional groups that establish
ligand–protein intermolecular clashes (Hann et al., 2001);
- Given all the above, FBDD projects can lead to increased
HIT rates and discovery of novel fragments interesting from
different points of view (binding affinity, synthetic accessibility,
intellectual property).
Historically, first FBDD projects were applied by a technique
named “SAR by NMR” (structure-activity relationship by
nuclear magnetic resonance) (Shuker et al., 1996). In this
paper, authors successfully developed a potent compound
with nanomolar affinity to FK506 binding protein (FKBP)
by merging two building blocks. Except for NMR, protein-
fragment interacting patterns are characterized by other
biophysical methods such as X-ray crystallography, surface
plasmon resonance (SRC), high concentration screening (HCS)
assays, isothermal titration calorimetry (ITC), fluorescence
correlation spectroscopy and many more (Sun et al.,
2011). The choice of a particular method depends on the
previous experience in FBDD projects and also the size of
fragment libraries.
Until now, fragment-based drug discovery (FBDD) method
resulted in FDA approval of three kinase inhibitors—
vemurafenib (Bollag et al., 2012), venetoclax (Deeks, 2016),
and erdafitinib (Markham, 2019). These excellent textbook
examples of FBDD are developed by different biophysical
methods; nevertheless, the present review focuses on various
in silico techniques frequently used in fragment identification
and optimization.
In recent years, experimental screening procedures may
be replaced by computational methods to reduce the costs
and time for early stages of FBDD project (Alves Avelar
et al., 2019; Ruzic et al., 2019). It appears that in silico studies
may support kinase drug discovery at almost every stage of
fragment-based drug design projects. Various ligand-based
virtual screening (Giordanetto et al., 2011), structure-based
(Warner et al., 2006; Zhao et al., 2012), and quantum mechanical
(Machrouhi et al., 2010) techniques have been proved as
successful in novel fragment identification. Before running
any virtual screening protocol, computational chemists
must pay attention to the valid preparation of fragment
library database. The fragment library databases should
obey the aforementioned Rule of 3 (RO3); additionally,
their chemical properties are filtered through certain
software which removes possible toxicophores and pan-
assay interference compounds (PAINS) (Baell and Walters,
2014). Nowadays, computational chemists may use kinase
fragment libraries which may assist faster identification of novel
hinge binding motifs. Moreover, fragments that target distal
pockets from the ATP binding pocket could be scanned by
allosteric kinase library, such as Enamine Allosteric Kinase
Library (https://enamine.net).
Case Studies
Identification of PI3K p110β selective fragment
Intracellular lipid kinases that transfer a phosphate group
from ATP to certain cell membrane’s phospholipids
(Phosphoinositide-4,5-biphosphate, PIP2) belong to the family
of phosphoinositide 3-kinases (PI3K). These enzymes regulate
important cellular events and present interesting drug targets in
anticancer drug discovery. Giordanetto et al. (2011) successfully
identified fragments that showed selective p110β inhibition. At
the time this study was performed, the crystal structure of p110β
isoform was not available. Consequently, the homology model
was built in MODELLER (Webb and Sali, 2016) by using the
crystal structure of p110γ isoform. In this study, authors used
AstraZeneca’s virtual fragment database and subjected 183,330
fragments to a molecular docking study in GLIDE software
(Schrödinger, New York). The poses and orientation of the
fragments in the ATP binding pocket were inspected, as well
as hydrogen bonding interactions with amino acid residues in
the hinge region, affinity and selectivity pocket. The authors
reported five chemical classes of fragments (Figure 7A) based on
the different heterocyclic rings interacting with the hinge region
in p110β and their in vitro enzymatic profiles against four human
PI3K isoforms (p110α, p110β, p110γ, and p110δ). Overall, the
hit rate achieved from this screening was 8.57%, indicating good
performance of the molecular docking-based search for novel
and chemically interesting fragments as PI3K hinge binders. The
authors continued this study with the morpholine derivative,
compound (1) (Figure 7B), which showed moderate potency
against p110β (IC50 = 34µM), but its inhibition of the other
p110 isoforms was not determined at the tested concentrations.
In the following study, authors aimed to improve the affinity
of the compound (1) by substituting the dimethylamino group
with a more voluminous 2-(benzylamino) moiety (Giordanetto
et al., 2012). The novel compound (2) showed improved potency
(IC50 = 1.9µM) and efficiency (LE = 0.37 and LLE = 4.52)
toward p110β. The rationale for this chemical modification relies
on the observation that the bulkier substituents might target
amino acid residues M804 and W812 in the proximal selectivity
pocket. Finally, compound (3) was synthesized by introducing
the naphthyl group, which in turn attributed to the nanomolar
potency (IC50 = 0.093µM) and improved p110β selectivity
profile of compound (3).
Identification of mitogen-activated protein
kinase-interacting kinase 1 inhibitors
Mitogen-activated protein (MAP) kinase interacting kinases 1
and 2 (MNK1 and MNK2) carry out phosphorylation reaction
of eukaryotic translation initiation factor 4E (eIF4E) on serine
209 (Wendel et al., 2007). This translation factor is involved
in different cellular pathways, such as Ras/Raf/MEK/ERK and
PI3-kinase/protein kinase B (Akt) signaling pathways (Proud,
2015). The overexpression of phosphorylated eIF4E leads to
several malignant diseases, such as lymphomas, breast cancer,
and glioblastoma (Astanehe et al., 2012). The significance of
MNK1/2 enzymes in malignant transformation of the cell has led
to high demand for drug design of MNK1/2 inhibitors.
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FIGURE 7 | (A) Presentation of the identified scaffolds by in vitro biochemical screening as PI3K inhibitors (hinge interacting moieties are labeled in red), Ar—presents
carbocyclic or heterocyclic aromatic rings; (B) the scheme of lead optimization of the selected morpholine derivatives.
One remarkable study was performed in 2010, where
Oyarzabal et al. identified a highly potent and efficient fragment
entirely by in silico modeling. In this comprehensive study,
authors combined different virtual screening techniques to
identify pharmacological tools for MNK1 inhibition. Initially,
the Centro Nacional de Investigaciones Oncológicas (CNIO)
database was filtered according to the molecular weight
(<300 Da) and calculated solubility values (threshold −4
mol/L). By performing this prefiltering procedure, the authors
extracted 42,168 fragment-like compounds for virtual screenings
(Oyarzabal et al., 2010).
Availability of the crystal structure of MNK2 complexed
with staurosporine (PDB: 2HW7) enabled creating minimal
substructure, required for crucial interactions with MNK2
(Figure 8). The GOLD software (Jones et al., 1997) used
in this study was able to reproduce the binding mode of
staurosporine in MNK2. The virtual substructure was docked
in the crystal structure of MNK1 (PDB: 2HW6) to similarly
elucidate crucial amino acid interactions in the ATP binding
pocket. MNK1 pharmacophore prepared in this way was used for
pharmacophore fitting study, as a molecular docking alternative
and 92 compounds were extracted according to their goodness of
fit with the pre-defined substructure.
Structure-based virtual screening protocols were combined
with ligand-based virtual screenings of CNIO database and
external virtual database of compounds collected by the
authors who performed this study. These strategies involved
2D-substructural searches, 2D Tanimoto structural similarity,
Feature Trees similarity, and three-dimensional shape and
electrostatic similarities based on two reported MNK1 inhibitors.
Finally, the authors selected 1,236 compounds for biochemical
MNK1 assay and 26 of them were active. The hit ratio
of this screening was 2.10% and 10 different scaffolds were
represented. Interestingly, one compound (Figure 8, compound
29) demonstrated nanomolar MNK1 (IC50 = 646 nM) and
MNK2 (IC50 = 575 nM) inhibition. Additionally, at the cellular
level, compound 29 showed an antiproliferative effect against
acute myeloid leukemia cell line (MV4:11, EC50 = 17µM) with
dose-dependent decrease in phosphorylation on serine 209 in
eIF4E. In conclusion, this study identified 26 hit molecules as
MNK1 inhibitors, with 19 of them as fragments with high ligand
efficiency values. Among the 26 identified hits, there were 10
diverse chemotypes represented for further drug design studies.
Researchers from A-STAR were particularly interested in
imidazopyridazine scaffold (chemotype III in the study of
Oyarzabal et al.) as a starting fragment for lead optimization of
MNK1/2 inhibitors (Yang et al., 2018). Extensive SAR study of
imidazopyridazine derivatives was based on in silico conclusions
defined in their previous computational study (Kannan et al.,
2017). Concisely, researchers in this study aimed to modify the
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FIGURE 8 | (A) Crystal structure of MNK-2 complexed with staurosporine (PDB: 2HW7); the atoms of the substructure used in the study of pharmacophore fitting
screening are labeled in green; (B) the lead optimization strategies starting from fragment ET-38766 to clinical candidate ETC-206.
heterocyclic core in positions 3 and 6, with later modification
of the imidazopyridazine scaffold (swapping cores strategy). All
the derivatives synthesized in this study were firstly examined
by molecular docking studies in Glide 2017-3 software (www.
schrodinger.com). By detailed computational analysis of the
important amino acid residues in the ATP pocket of MNK1/2
kinases, researchers performed initial lead optimization of the
fragment (compound ET-38766) to compound 27 (Figure 8B).
Novel compound 27 bears imidazopyrazine scaffold, with
improved potency against MNK-1 and MNK-2, cell permeability
and improved pharmacokinetic properties. After finding optimal
substituents in positions 3 and 6, the final step of lead
optimization was focused on detailed DFT study to select the
final heterocyclic core of MNK1/2 inhibitors. Initially, it was
unclear from molecular dynamics (MD) simulations whether
the imidazopyrazine N-7 contributes favorably to the binding
affinity of MNK inhibitors. To examine this, the authors
performed DFT study and demonstrated that N-7 is mostly
solvent exposed, thus the final selected heterocyclic core was
imidazopyridine. The most promising compound 48 (Figure 8B)
later designated as ETC-206, was presented as superior compared
to other derivatives in the study. This compound was investigated
for the synergism with dasatinib in vivo and currently is
in phase I clinical trial for the blast crisis chronic myeloid
leukemia (BC-CML).
Computational approaches in rational discovery of allosteric
kinase inhibitors
Although targeting of highly conserved ATP-binding site by Type
I and Type II inhibitors provides limited selectivity, inhibiting
multiple kinases with a single small-molecule inhibitor was
proven to be a useful strategy for therapeutic intervention.
However, development of highly selective small-molecule kinase
inhibitors remains a pressing concern where targeting of
allosteric sites emerged as a promising approach (Wu et al.,
2015a). Some of the advantages of targeting allosteric sites include
increased selectivity and low toxicity of such inhibitors due
to low evolutional conservation of allosteric sites compared to
orthosteric (ATP-binding) sites (Fang et al., 2013). Additionally,
overcoming of point mutation-associated drug resistance,
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especially for mutations in the ATP-binding site reported for
almost all of ATP-competitive inhibitors, could be another
advantage of developing allosteric kinase inhibitors (Gibbons
et al., 2012).
While exploitation of allosteric sites represents a very
promising strategy, it remains challenging from the aspect of
rational drug discovery. Some of the major obstacles include
identification of allosteric binding sites, which are usually
hidden in less populated higher energy conformations of
the proteins. Those conformations are poorly accessible to
current experimental methods of structural biology (Lu et al.,
2018a). Additionally, allosteric effectors are susceptible to “mode
switching,” where minor chemical modification of ligand induces
critical change in activity (Wenthur et al., 2014). Although known
CADD workflows for discovery of drugs directed to orthosteric
binding sites are being used in allosteric inhibitors discovery
(Rastelli et al., 2014; Schoepfer et al., 2018), they provide limited
utility rising the need for development of more spatialized tools
and workflows (Greener and Sternberg, 2018).
Identification of allosteric pockets is a crucial first step in
rational discovery of allosteric inhibitors. As will discussed
below, a plethora of computationally inexpensive methodologies
have been developed for this purpose and many of them are even
implemented as web servers. While these methodologies provide
fast and inexpensive highway in the discovery of druggable
allosteric pockets, proper understanding of the allosteric
mechanism is impossible without considering underlying
conformational landscape and free-energy profiles where
more computationally demanding molecular dynamics based
approaches have a predominant role. In this review, we discuss
few examples of computational methodologies used for direct
discovery of novel allosteric sites and/or allosteric kinase
inhibitors. For detailed description of recent breakthroughs
in computational methodologies used for allosteric inhibitors
discovery in general, the interested reader is referred to the
recent reviews (Wagner et al., 2016; Lu et al., 2019).
Automatic Computational Tools/Web Servers to
Investigate Allostery
Structure-based computational tools AlloSite and recently
advanced descendant AllositePro (http://mdl.shsmu.edu.cn/
AST/) are intended for fast detection of allosteric site in input
PDB structures. Initial detection of allosteric sites is based on
Fpocket, a fast open source protein pocket detection software
package based on Voronoi tessellation (Le Guilloux et al.,
2009). While Allosite uses a machine-learning model to re-
rank detected pockets in terms of their allosteric character,
AllositePro additionally implements normal-mode analysis
(NMA) perturbation with elastic network models to account
for protein flexibility. NMA is a technique developed for
investigation of the vibrational motion of a harmonic oscillating
system in the immediate vicinity of its equilibrium. Under
assumption that the potential energy landscape in the vicinity of
a minimized atomic structure is approximately harmonic, NMA
eliminates the need to integrate the equations of motion and
makes NMA much less computationally demanding compared
to MD (Bahar and Rader, 2005). Zhang et al. demonstrated
utility of AllositePro in identification of novel allosteric site
on CDK2 kinase. Existence of novel site was validated in
mutagenic analysis (Song et al., 2017). Recently, the same group
developed AlloFinder, integrated allosterome mapping, and
virtual screening workflow implemented as web server (http://
mdl.shsmu.edu.cn/ALF/). AlloFinder relies on AllositePro
algorithm for detection of allosteric sites, Allolike filter for
pre-filtering of ligand library to enrich allosteric-like compounds
(Wang et al., 2012), AutoDock Vina algorithm for docking (Trott
and Olson, 2010), and Alloscore empirical scoring function for
scoring allosteric modulator-protein complexes (Li et al., 2016).
In the final step, alosterome mapping is used to detect highly
similar allosteric sites among known human allosteric sites and
to rule out selective ligands. This approach was retrospectively
validated on several kinase targets (Huang et al., 2018).
CavityPlus (http://www.pkumdl.cn:8000/cavityplus/index.
php) is another web server for detection of potential allosteric
sites that works on similar principle (Xu et al., 2018). CavityPlus
is aimed to detect potential binding sites on the surface of a given
protein and rank them based on ligandability and druggability
scores. This server integrates several functionalities: CAVITY
for detection and scoring of potential binding sites (Yuan
et al., 2013); CavPharmer for generation of receptor-based
pharmacophores (Chen et al., 2014); CorrSite for prediction of
allostery based on NMA motion correlation analysis between
allosteric and orthosteric sites (Ma et al., 2016); CivCys for
detection of binding sites for covalent inhibitors (Zhang et al.,
2017). Functionalities of CavityPlus were successfully used for
identification of allosteric binding site on Polo-like kinase 1
(Plk1). Subsequent molecular-docking-based virtual screening
on allosteric site resulted in identification of few potent Plk1
inhibitors (Yun et al., 2016).
Another successful implementation of web server based tools
for allosteric drug discovery is Kinase Atlas (https://kinase-
atlas.bu.edu/) (Yueh et al., 2019). Kinase Atlas is systematic
collection of mostly unexplored allosteric sites (binding hot
spots) calculated for 4,910 PDB structures of 376 distinct
kinases. The hot spots are identified by FTMap. This method
places molecular probes (small organic molecules) on a dense
grid around the protein and finds favorable positions using
an empirical energy function and CHARMM potential. After
clustering of obtained positions for each probe, regions that
bind several probe clusters are marked as hot spots (Kozakov
et al., 2015). Authors of the study identified novel allosteric
site on CDK2 and screened library of 1,280 molecules using
disulphide-based fragment screening. Two potent and novel
allosteric inhibitors were described.
Molecular Dynamics-Based Approaches to
Investigate Allostery
Molecular dynamics-based approaches in rational discovery of
allosteric kinase inhibitors have potential to provide exclusive
insight in atomic-level dynamical mechanism of allostery,
to explore conformational landscape and capture kinase
conformational states inaccessible to current experimental
methodologies. Therefore, molecular-dynamics-based
approaches, even though being computationally intensive,
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could detect previously unknown conformations and hidden
allosteric binding pockets (Guo and Zhou, 2016; Lu et al., 2018a).
Combination of conventional MD simulations with other
standard SBDD approaches resulted in identification of novel
allosteric sites and discovery of novel allosteric ligands in several
cases. For example, Perez et al. identified novel inhibitory
allosteric site and inhibitors of p38α by using MD simulations
starting from the X-ray structure of binary complex of p38α
and its interacting partner MAPK-activated protein kinase 2
(MK2). MD simulations permitted definition of pharmacophoric
features of small peptide inhibitors derived from sequence of
MK2. Subsequent virtual screening study resulted in first small
molecule allosteric inhibitor for identified binding site (Gomez-
Gutierrez et al., 2016). Cournia et al. verified existence of
allosteric site on human PI3Kα previously described in murine
PI3Kα using combination of FTMap, MD, and in vitro assays.
Intriguingly, MD simulations revealed different binding mode of
studied allosteric inhibitor in murine, WT, and mutant forms of
PI3Kα and consequent differences in propagation of allosteric
signal to orthosteric ATP-binding site (Gkeka et al., 2015).
Computational costs of insufficient conformational sampling
often limit application of conventional MD simulations in
investigating allostery phenomena. Currently, there is a large
gap between the time scale which can be reached in MD
simulations and that observed in experiments. Several strategies
for enhancing the sampling of MD simulations have been
proposed (Aci-Seche et al., 2016; Yang et al., 2019). Two
recently reported studies demonstrating full power of enhanced
sampling methods (Markov-state modeling based adaptive
sampling and parallel tempering in the well-tempered ensemble)
are discussed below with special reference to atomic-level
description of allosteric communication and discovery of cryptic
allosteric pockets.
Pande et al. investigated activation pathway of c-Src
kinase using massively distributed MD simulations (550 µs)
on Folding@HOME (Shirts and Pande, 2000) Markov-state
modeling (MSM) and adaptive sampling algorithms in order
to provide description of factors underlying thermodynamics
and kinetics of c-Src activation and to identify key structural
intermediates (Shukla et al., 2014). Briefly, MSM models
represent kinetical description of a system’s underlying free-
energy landscape, useful for characterization of probability of
dynamical transitions between conformational states identified
in many independent MD simulations and for extrapolation of
long time system’s behavior (Sengupta and Strodel, 2018). In
this study intermediate conformational state which could be
stabilized to block the c-Src activation pathway, was described
through MSM analysis for the first time. Further analysis on
identified c-Src conformational state revealed the existence
of allosteric pocket and surprisingly high structural similarity
to known complex of CDK2 bound to allosteric inhibitor—
ANS (Betzi et al., 2011). Further simulations confirmed
binding of ANS to the novel allosteric site of c-Src and
blockage of activation process by stabilization of intermediate
states. Additionally, the long-range residues coupling analysis
identified myristate-binding pocket as another potential target
for development of allosteric modulators of c-Src. Taken together,
results of this study highlighted large-scale MD coupled with
MSM modeling as an indispensable tool for identification of
novel conformational states, potential allosteric pockets, and
study of mechanisms of allostery in kinases.
In another example, authors explored the possibility of
bidirectional communication between allosteric so-called PIF-
pocket and ATP-binding site in PDK1 protein kinase using
a combination of experimental techniques and enhanced-
sampling simulations [parallel tempering simulations in the
well-tempered ensemble (PT-WTE)] (Schulze et al., 2016).
Results of PT-WTE MD revealed bidirectional mechanisms of
communication between the ATP-binding site and allosteric site.
Interestingly, this study for the first time demonstrated how
different ligands which bind to the ATP-binding site differently
modulate responses of allosteric site in interaction with a partner
protein (e.g., enhance or inhibit interaction). Providing computer
platform for rational design of allosteric modulators, the authors
of this study opened an exciting avenue for future discovery of
novel class of kinase inhibitors with less on-target side effects and
more specific modulation of signaling pathways.
Case Study
Rational design of clinical candidate Asciminib—allosteric
Bcr-Abl1 inhibitor
Asciminib belongs to a class of drugs designed to inhibit Bcr-
Abl by binding to an allosteric pocket known as myristate-
binding pocket. Rational development of Asciminib started
with fragment-based screening using NMR assay (Schoepfer
et al., 2018). Although determined NMR-based dissociation
constants (Kd) for fragment hits were satisfactory, none of
the fragments were active in biochemical and cellular assays.
Subsequent X-ray studies revealed inability of fragment hits
to induce assembled inactive state by bending of helix I,
previously reported as conformational change important or
autoinhibition of Abl by myristoilation (Nagar et al., 2003).
Following this finding, the authors established another screening
assay, the NMR-based conformational assay, which monitors
the conformational state of C-terminal helix I (Jahnke et al.,
2010). NMR-based conformational assay was used to investigate
identified fragments and series of known allosteric modulators—
derivatives of GNF-2 (Adrian et al., 2006; Figure 9). Results of
the study revealed that compounds which bind to myristoyl
pocket and do not induce helix I bending were actually
functional activators of Abl1 (by interfering with autoinhibition
mechanism of Abl1). Critical bending of helix I was found
to be induced by the presence of CF3O– group from GNF-2.
Based on these findings, CADD techniques (molecular docking,
similarity and pharmacophore searches) were used to design
compound X in respect to X-ray structure with bent helix I
conformation. Subsequent introduction of CF3O– group finally
led to the first active allosteric inhibitor. Molecular modeling
techniques were used in combination with X-ray crystallography
in order to optimize potency and drug-like properties of the
compound. Although only standard CADD techniques were
reported in the discovery of Asciminib, recent application of
molecular dynamics-based approaches demonstrated utility of
such techniques in examination of mechanisms of resistance
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FIGURE 9 | Discovery of Asciminib (Schoepfer et al., 2018). (A) Representation of initial hypothesis regarding bending of helix I (orange). Assembled inactive state of
ABL1 kinase in complex with myristic acid (orange sticks) (PDB: 1OPL, SH3, and SH2 domains omitted for clarity) is superimposed on ABL1 in complex with fragment
2 (green sticks) (PDB: 3MS9). Steric clash between isoleucin I521 (orange sticks) on helix I and fragment 2 prevents full bending of helix I and formation of assembled
inactive state of ABL1. Helix I is not visible in the PDB: 3MS9. (B) Medicinal chemistry progression from fragment 2 to fragment derived hit 4, first active hit–compound
5 and finally clinical candidate—Asciminib.
and effects of dual targeting of ATP-binding and allosteric site
providing rationale for development of novel drugs (El Rashedy
et al., 2018; Meng et al., 2018; Zhan et al., 2019).
Machine learning methods to predict kinase-compound
interactions
Nowadays, we are seeing the widespread use of machine learning
in many areas, including pharmaceutical industry, especially
in drug design. Popular computational methods initially
used in pharmaceutical research were quantitative structure
activity relationships (QSAR) and quantitative structure property
relationship (QSPR), which were adequate for small datasets.
However, with the rapid growth of databases (thanks to
methods such as high-throughput in vitro screening and X-
ray crystallography), it became inevitable to develop different
in silico tools that can manage bigger data (Ekins, 2016).
Today, many different machine learning methods such as
support vector machines (SVM), k-Nearest Neighbors, Artificial
Neural Networks (ANN), Deep Learning (DL), etc. are used
in pharmaceutical research and they can be applied in various
processes of drug design from virtual screening to de novo drug
design (Buchwald et al., 2011; Drewry et al., 2017; Konze et al.,
2019; Kuthuru et al., 2019; Lee et al., 2019; Zhavoronkov et al.,
2019).
Many different machine learning models were created for
the prediction of drug–target interactions (DTI), and many
DTI methods have been applied to the protein kinases family
(Kuthuru et al., 2019). Unlike LB and SB methods, DTI
prediction uses the information from both protein and ligand
and these methods can be similarity based or descriptor-based.
One of the first similarity-based methods for identification
of drug–target interactions was introduced by Yamanishi
et al. in 2008. It used the known drug structure, protein
sequence and drug–target interaction network to determine
unknown ligand–target interactions. The main hypothesis is
that two compounds that have high structure similarity might
probably interact with similar target proteins, and vice versa
two proteins with high sequence similarity might probably
interact with similar drugs (Yamanishi et al., 2008). On the
other hand, descriptor-based models use feature vectors from
known drug structures and protein sequences, as inputs for
machine learning methods, such SVM, AAN, DL, etc. In
2011, Buchwald et al. used SVM to prepare the model for
prediction of protein kinases–ligand interactions. They used
a set of binding data obtained from 113 different protein
kinases and 20 inhibitors obtained through ATP site-dependent
binding competition assays. They focused on vector features
that describe the structure of molecules that are connected with
certain chemical environment–protein active site sequence and
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created a SVM model with good predictivity (Buchwald et al.,
2011).
Recently, the use of ANN, especially deep learning methods
saw a significant increase in the process of drug design (Ekins,
2016; Merk et al., 2018; Putin et al., 2018; Konze et al.,
2019). Deep generative models are utilizing neural networks to
generate new objects (drugs) with desired properties (for example
activity, Ki, IC50). These methods should be able to produce
chemically correct structures without the need for including
fragment libraries and/or rules for their combination (Merk
et al., 2018). The ability to produce novel chemical structures
with certain properties makes deep generative models suitable
for the discovery of novel possible therapeutics (Zhavoronkov
et al., 2019). In 2018, Merk et al. applied generative models
to come up with novel bioactive, synthesizable drugs. They
trained the model with more than 500,000 SMILES of bioactive
compounds with their activity properties extracted from the
ChEMBL (KD, Ki, IC/EC50 values <1µM). Additionally, the
model was fine-tuned to enable the de novo generation of target-
specific ligands on retinoid X receptors (RXR) and/or peroxisome
proliferator-activated receptors (PPAR). Finally, none of the
generated compounds was identical to compounds from the
training sets, and they were residing within the RXR/PPAR region
of the fine-tuning set (Merk et al., 2018).
Case Studies
Predictive proteochemometric models for kinases derived
from 3D protein field-based descriptors
Subramanian et al. described the development of
proteochemometric models for 1,572 inhibitors and 95
kinases obtained from Kinase SARfari (https://chembl.gitbook.
io/chembl-interface-documentation/legacy-resources#kinase-
sarfari) and CHEMBL database, using 3D structure of proteins
and active and inactive ligands. Proteins were described
with molecular interaction fields derived from Schrödinger’s
WaterMaps, while different 1D, 2D, and 3D descriptors were
used to describe the ligands. Separate training sets were created
for the ligands and targets. Different methods were used for
preparation of the proteochemometric models: support vector
machines (SVM) and random forests (RF). The ligand prediction
model was trained on the ligand training set and was used
for ligand prediction model and target training set for target
predicting model. In the end, they validated all the models using
internal and external validation. This approach allows creation
of not only predictive proteochemometrics model for protein
kinases, but also preparation of visually interpretable models.
This allows interpretation of kinase–ligand interactions, which
can be used, for example, for optimization of ligand in order
to achieve optimal activity and/or selectivity. Having visually
interpretable models is the advantage compared to classical DTI
methods that use only 2D information (Subramanian et al., 2013,
2016).
Deep learning model for identification of potent discoidin
domain receptor 1 kinase inhibitors
Recently, Zhavoronkov et al. created a deep generative model
for de novo small-molecule design—GENTRL (GENerative
Tensorial Reinforcement Learning). Besides the effectiveness of
a compound against a given biological target, GENTRL also
takes into account its dissimilarity from other molecules in the
literature and patent space, as well as its synthetic feasibility.
For the proof-of-concept GENTRL was used to design potential
Discoidin domain receptor 1 (DDR1) kinase inhibitors. Data
was collected from different data sets: ZINC data set, known
DDR1 kinase inhibitors data set, common kinase inhibitors,
molecules with activity on non-kinase targets, patent data, and
used to train the model. The model was generated by combining
reinforcement learning with a reward, variational inference,
and tensor decompositions. Finally the randomly elected six
compounds that have not been previously published or patented
were designed, synthesized, and experimentally tested. The whole
process lasted only 46 days, which suggests that the application of
drug design methods such as this will reduce the time and cost of
drug discovery process (Zhavoronkov et al., 2019).
CONCLUDING REMARKS
In silico approaches are viable, usually cheaper and faster
alternative to experimental drug discovery techniques. This
review summarizes the most important computational tools
that have led to the discovery of kinase inhibitors, many of
which are in clinical use today as promising anticancer drugs.
Computational approaches, such as QSAR modeling, ligand-
based and structure-based virtual screening, molecular docking,
molecular dynamics, quantum mechanics, fragment-based drug
design, and machine learning methods, provide unique insight in
the conformational landscape of kinases, structural requirements
for inhibitory activity, binding modes and atomistic mechanisms
of allostery, which represent indispensable information for
rational de novo design. One of the main advantages of
computational approaches is the possibility of introduction of
new groups on the known scaffolds and in silico prediction
of activities and binding affinities. Known scaffolds of the
approved KIs include pyrimidine (imatinib, dasatinib, nilotinib),
quinazoline (erlotinib, gefitinib, afatinib, vandetanib), pyridine
(sorafenib), pirrolopyridine (vemurafenib), pyrazolopyridine
(ibrutinib) etc. In silico modification of these scaffolds resulted
in the design of many kinase inhibitors with enhanced
predicted activities and binding affinities which can serve
as lead compounds for further synthesis and preclinical
testing. New chemical scaffolds that possess kinase inhibitory
activity (imidazopyridazine, imidazopyridine, isoquinoline,
phenazinamine, etc.) have also been proposed by computational
approach and represent a good starting point for discovery
of new kinase inhibitors. Due to increases in computational
power, algorithmic improvements and increased accuracy, in
silico approaches are yet expected to radically shape the era of
kinase inhibitor discovery. Of note is to emphasize that not
all drug discovery projects could be initiated and guided only
with computational studies. The computational chemist must
be aware of the structural biology of the studied targets, their
dynamical changes influenced upon fragment/ligand binding.
Whenever possible, it is advised to start CADD studies with
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experimental data and continue in silico optimization with
combined modeling approaches, as much as possible. This
review highlights the recent advances in discovery of kinase
inhibitors by in silico approaches and can be useful for future
design and synthesis of new kinase inhibitors as anticancer drugs.
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